Effect of Bevacizumab and VEGF on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2011 by National Cancer Institute (NCI).
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00898794
First received: May 9, 2009
Last updated: August 6, 2013
Last verified: June 2011
  Purpose

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about the effect of bevacizumab and VEGF on platelet clustering.

PURPOSE: This research study is looking at the effect of bevacizumab and VEGF on platelet clustering in patients with cancer who are receiving bevacizumab.


Condition Intervention
Unspecified Adult Solid Tumor, Protocol Specific
Unspecified Childhood Solid Tumor, Protocol Specific
Biological: bevacizumab
Other: coagulation study
Other: laboratory biomarker analysis
Other: platelet aggregation test

Study Type: Observational
Official Title: Influence of Bevacizumab and VEGF on Platelet Aggregation

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Influence of bevacizumab on platelet aggregation [ Designated as safety issue: No ]
  • Influence of VEGF on platelet aggregation [ Designated as safety issue: No ]
  • Influence of VEGF or bevacizumab on cyclooxygenesis [ Designated as safety issue: No ]
  • Correlation between medication sequence and platelet aggregation [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: October 2007
Estimated Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • To determine the influence of bevacizumab on platelet aggregation in patients receiving bevacizumab for cancer.
  • To determine the influence of VEGF on platelet aggregation.
  • To determine the influence of VEGF or bevacizumab on cyclooxygenesis.
  • To determine if the sequence of medication plays a role in platelet aggregation.

OUTLINE: Blood samples are collected before and after bevacizumab infusion. Samples are analyzed for measurements of platelet aggregation, coagulation parameters, and endothelial activation (e.g., fibrin fragment F1 and 2, thrombin and antithrombin complex, soluble P-selectin, Von Willebrand factor and factor VIII, tissue factor, and endothelin 1).

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Receiving bevacizumab for cancer

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00898794

Locations
Switzerland
Kantonsspital Graubuenden Recruiting
Chur, Switzerland, CH-7000
Contact: Roger von Moos, MD    41-81-256-6646    roger.vonmoos@ksgr.ch   
Sponsors and Collaborators
Kantonsspital Graubuenden
Investigators
Principal Investigator: Roger von Moos, MD Kantonsspital Graubuenden
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00898794     History of Changes
Other Study ID Numbers: KSGR-GR-01-07, CDR0000631252
Study First Received: May 9, 2009
Last Updated: August 6, 2013
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
unspecified adult solid tumor, protocol specific
unspecified childhood solid tumor, protocol specific

Additional relevant MeSH terms:
Neoplasms
Bevacizumab
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 19, 2014